AU2013316700B2 - Peptide antagonists of the vasopressin-2 receptor - Google Patents

Peptide antagonists of the vasopressin-2 receptor Download PDF

Info

Publication number
AU2013316700B2
AU2013316700B2 AU2013316700A AU2013316700A AU2013316700B2 AU 2013316700 B2 AU2013316700 B2 AU 2013316700B2 AU 2013316700 A AU2013316700 A AU 2013316700A AU 2013316700 A AU2013316700 A AU 2013316700A AU 2013316700 B2 AU2013316700 B2 AU 2013316700B2
Authority
AU
Australia
Prior art keywords
seq
protein
amino acid
da2a
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013316700A
Other languages
English (en)
Other versions
AU2013316700A1 (en
Inventor
Nicolas Gilles
Christiane MENDRE
Bernard Mouillac
Loic Quinton
Helen REINFRANK
Denis SERVENT
Ralph WITZGALL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liège
University of Regensburg
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Original Assignee
University of Liège
University of Regensburg
Centre National de la Recherche Scientifique
Commissariat a lEnergie Atomique CEA
Institut National de la Santé et de la Recherche Médicale
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Liège, University of Regensburg, Centre National de la Recherche Scientifique, Commissariat a lEnergie Atomique CEA, Institut National de la Santé et de la Recherche Médicale, Commissariat à l'Énergie Atomique et Aux Énergies Alternatives filed Critical University of Liège
Publication of AU2013316700A1 publication Critical patent/AU2013316700A1/en
Application granted granted Critical
Publication of AU2013316700B2 publication Critical patent/AU2013316700B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
AU2013316700A 2012-09-17 2013-09-17 Peptide antagonists of the vasopressin-2 receptor Active AU2013316700B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306120.2A EP2708235A1 (en) 2012-09-17 2012-09-17 Peptide antagonists of the vasopressin-2 receptor
EP12306120.2 2012-09-17
PCT/IB2013/058615 WO2014041526A1 (en) 2012-09-17 2013-09-17 Peptide antagonists of the vasopressin-2 receptor

Publications (2)

Publication Number Publication Date
AU2013316700A1 AU2013316700A1 (en) 2015-04-09
AU2013316700B2 true AU2013316700B2 (en) 2017-10-12

Family

ID=46963639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013316700A Active AU2013316700B2 (en) 2012-09-17 2013-09-17 Peptide antagonists of the vasopressin-2 receptor

Country Status (14)

Country Link
US (1) US9631001B2 (cg-RX-API-DMAC10.html)
EP (2) EP2708235A1 (cg-RX-API-DMAC10.html)
JP (1) JP6392758B2 (cg-RX-API-DMAC10.html)
KR (1) KR102135954B1 (cg-RX-API-DMAC10.html)
CN (1) CN104684574B (cg-RX-API-DMAC10.html)
AU (1) AU2013316700B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015005750B1 (cg-RX-API-DMAC10.html)
CA (1) CA2884361C (cg-RX-API-DMAC10.html)
DK (1) DK2895189T3 (cg-RX-API-DMAC10.html)
ES (1) ES2664747T3 (cg-RX-API-DMAC10.html)
MX (1) MX362664B (cg-RX-API-DMAC10.html)
NZ (1) NZ706202A (cg-RX-API-DMAC10.html)
RU (1) RU2015114320A (cg-RX-API-DMAC10.html)
WO (1) WO2014041526A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021528476A (ja) * 2018-06-28 2021-10-21 サルアクア ダイアグノスティックス， インコーポレイテッド ハプトグロビン関連タンパク質と関係する組成物および方法
EP3929209A1 (en) * 2020-06-24 2021-12-29 Commissariat à l'Energie Atomique et aux Energies Alternatives Vasopressin-2 receptor antagonist peptides and uses thereof
CN115820734B (zh) * 2022-11-11 2024-12-13 北京希诺谷生物科技有限公司 中枢性尿崩症疾病模型犬的建立方法
CN116425888B (zh) * 2023-04-24 2024-11-05 徐州医科大学 一种多肽tat-v2r1c及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2007019267A1 (en) 2005-08-03 2007-02-15 Mineuet Therapeutics Ltd. MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR α (TNF-α) AND TREATING HUMAN DISEASES OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-α
US8343760B2 (en) * 2008-06-05 2013-01-01 University Of Maryland, Baltimore p53 activator peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"RecName: Full=Dendrotoxin-B; AltName: Full=Venom basic protease inhibitor B;", DATABASE UniProt, Database accession no. P00983, URL: EBI, *
"RecName: Full=Protease inhibitor mulgin-1; Flags: Precursor;", DATABASE UniProt, Database accession no. Q6ITC1, URL: EBI, *
HIDETOSHI INAGAKI ET AL, TOXICON, ELMSFORD, NY, US, vol. 59, no. 1, doi:10.1016/J.TOXICON.2011.10.005, ISSN 0041-0101, (20111007), pages 74 - 80, (20111019), *

Also Published As

Publication number Publication date
RU2015114320A (ru) 2016-11-10
NZ706202A (en) 2018-06-29
CN104684574B (zh) 2018-08-31
MX362664B (es) 2019-01-31
AU2013316700A1 (en) 2015-04-09
ES2664747T3 (es) 2018-04-23
WO2014041526A1 (en) 2014-03-20
EP2708235A1 (en) 2014-03-19
EP2895189B1 (en) 2018-01-10
CA2884361C (en) 2022-03-22
BR112015005750A8 (pt) 2018-04-17
KR102135954B1 (ko) 2020-07-21
JP6392758B2 (ja) 2018-09-19
EP2895189A1 (en) 2015-07-22
KR20150070172A (ko) 2015-06-24
BR112015005750B1 (pt) 2022-08-16
MX2015003225A (es) 2015-11-16
BR112015005750A2 (pt) 2017-12-12
CA2884361A1 (en) 2014-03-20
CN104684574A (zh) 2015-06-03
DK2895189T3 (en) 2018-04-16
JP2016500001A (ja) 2016-01-07
US9631001B2 (en) 2017-04-25
US20150252086A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
JP6321299B2 (ja) グルカゴン受容体アゴニスト
US9241967B2 (en) Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction
US9944675B2 (en) Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
ES3048909T3 (en) Long-acting amylin receptor agonists and uses thereof
US9631001B2 (en) Peptide antagonists of the vasopressin-2 receptor
CN103038248B (zh) Rhamm结合肽
Gleixner et al. [3H] UR-JG102–A Radiolabeled Cyclic Peptide with High Affinity and Excellent Selectivity for the Neuropeptide Y Y4 Receptor
KR20160075826A (ko) 중증 저혈당증의 치료를 위한 신규 화합물
EP4638482A2 (en) Peptide conjugates for labelling endogenous gipr and glp-1r
WO2023203127A1 (en) Alphabody-based degrader molecules
JP7617958B2 (ja) バソプレシン２受容体アンタゴニストペプチド及びその使用
Lee Development of the novel amylin receptor activators with nanomolar potency by peptide mutagenesis
AU2001247675A1 (en) Binding compounds and methods for identifying binding compounds
Richardson Design and evaluation of fluorescent and non-fluorescent bivalent ligands to explore their mode of action at neuropeptide Y receptors
WO2018017922A2 (en) Selective bfl-1 peptides
Bower Molecular Determinants of Amylin Receptor Agonism
WO2025186255A1 (en) Gipr inhibitors and methods of use
WO2011132938A2 (ko) Gpcr에 특이적으로 결합하는 gpcr-bpb
WO2008098308A1 (en) Agents and methods for treatment of cell proliferative diseases and conditions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)